Abstract:Telmisartan, an angiotensin II receptor blocker, has been widely used for hypertension. It has also been reported to improve insulin sensitivity in animal models of obesity and diabetic patients by targeting to the peroxisome proliferator-activated receptor (PPAR)-γ. High glucose/high lipid (HG/HL)-induced apoptosis of pancreatic β-cells impairs its function of insulin secretion and is generally believed to be the key factor in the development of diabetes. In this study, we investigated whether telmisartan exerted a protective effect against HG/HL-induced apoptosis and insulin secretion in vitro as well as in vivo; 10-μM telmisartan treatment significantly reduced HG (25 mM) or/and HL (0.4 mM palmitic acid) induced-cell apoptosis and greatly improved insulin secretion in INS-1 pancreatic β-cells, which is consistent in an obesity rat model induced by HG/HL diets. Furthermore, telmisartan treatment markedly reduced the protein level of GRP78, CHOP, and caspase 12, while increasing anti-apoptotic Bcl-2 protein expression. Moreover, telmisartan treatment significantly reduced intracellular ROS levels. Mechanistically, we demonstrated that PPARγ signaling pathway may be involved in the telmisartan protective effects, which were blocked by a PPARγ blocker, GW9662. In conclusion, the protective effect of telmisartan was mediated by an anti-ER stress-induced apoptotic and anti-oxidative pathway. SIGNIFICANCE OF THIS STUDY: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder worldwide pathologically characterized by hyperglycemia and insulin resistance. Long-term high glucose in the blood has been proposed to induce pancreatic β-cell loss and is generally believed to be the key factor in the development of diabetes. In the present study, we demonstrated that telmisartan, a common drug used for hypertension treatment, has a protective effect against high glucose/high lipid-induced cell apoptosis and greatly improves the insulin secretion function by inhibiting the oxidative stress and ER stress. Furthermore, this protective effect of telmisartan is mediated by the PPAR-γ signal pathway, which may provide a potential strategy against T2DM.

Anti-Apoptosis of Podocytes and Pro-Apoptosis of Mesangial Cells for Telmisartan in Alleviating Diabetic Kidney Injury

Autophagy protects against senescence and apoptosis via the RAS-mitochondria in high-glucose-induced endothelial cells.

Telmisartan Attenuates Diabetic Nephropathy Progression by Inhibiting the Dimerization of Angiotensin Type-1 Receptor and Adiponectin Receptor-1.

Tripterygium glycoside protects diabetic kidney disease mouse serum-induced podocyte injury by upregulating autophagy and downregulating β-arrestin-1.

Telmisartan protects against high glucose/high lipid‐induced apoptosis and insulin secretion by reducing the oxidative and ER stress

Effects of Telmisartan on Renoprotection and Podocalyxin Expression in Podocytes of Deoxycorticosterone Acetate/Salt-Hypertensive Rats

Renal expression of α-SMA in diabetic nephropathy and the protective effects of Telmisartan

Telmisartan on the Expression of Renin Receptor in the Kidneys of Diabetic Rats

Valsartan Attenuated Oxidative Stress, Decreased MCP-1 and TGF-β1 Expression in Glomerular Mesangial and Epithelial Cells Induced by High-Glucose Levels.

Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.

Telmisartan inhibits methylglyoxal-mediated cell death in human vascular endothelium

Astaxanthin attenuates diabetic kidney injury through upregulation of autophagy in podocytes and pathological crosstalk with mesangial cells

Telmisartan Protects Against Diabetic Vascular Complications in a Mouse Model of Obesity and Type 2 Diabetes, Partially Through Peroxisome Proliferator Activated Receptor-Γ-dependent Activity

Review: Potential protective effects of telmisartan on renal function deterioration

Telmisartan Attenuates the Growth of Epithelium-like Cells and Glomerular Injury in Spontaneously Hypertensive Rats

Inhibition of Integrin-Linked Kinase by Angiotensin II Receptor Antagonist, Irbesartan Attenuates Podocyte Injury in Diabetic Rats.

Protective effect of valsartan on the podocytes of diabetic rats

Protective Effect of Irbesartan by Inhibiting ANGPTL2 Expression in Diabetic Kidney Disease

Xuesaitong Protects Podocytes from Apoptosis in Diabetic Rats Through Modulating PTEN-PDK1-Akt-mTOR Pathway.

Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy mice

Tangshenning Attenuates High Glucose-Induced Podocyte Injury via Restoring Autophagy Activity through Inhibiting mTORC1 Activation